Tenderwize
Retour à la recherche

Open House Rebate Agreements for Formoterol, Glycopyrronium Bromide and Beclometasone, ATC R03AL09

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jun 03, 2027 · 278 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Formoterol, Glycopyrroniumbromid und Beclometason, ATC R03AL09

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

Structured data indicates EU funding (isEuFunded: true) but XML notice states no EU funds (FundingProgramCode: no-eu-fu...

The open-house model is explicitly not subject to procurement law; legal remedies may differ. The notice includes a not...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jul 2027
  • Conclusion of non-exclusive rebate agreements for pharmaceutical products containing Formoterol, Glycopyrroniumbromid, and Beclometason (ATC R03AL09).
  • Contract duration from earliest start (August 1, 2025) to July 31, 2027.
Afficher le résumé complet

This is an Open House model by AOK Bayern for non-exclusive rebate agreements on pharmaceutical products with active substances Formoterol, Glycopyrroniumbromid, and Beclometason (ATC R03AL09). Any qualified pharmaceutical company can join; no competitive selection. The contracts run from August 1, 2025 to July 31, 2027, with possible early termination. Submissions can be in paper or with qualified electronic signature. No estimated contract value is provided.

Risques

Structured data indicates EU funding (isEuFunded: true) but XML notice states no EU funds (FundingProgramCode: no-eu-fu...

The open-house model is explicitly not subject to procurement law; legal remedies may differ. The notice includes a not...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Proof of authorization (commercial register extract or power of attorney).

Eligibility

  • Only pharmaceutical companies are eligible.

Administrative

  • Submission of signed contract, annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and self-declaration of reliability.

Les exigences peuvent être incomplètes.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open House Rebate Agreements for Formoterol, Glycopyrronium Bromide and Beclometasone, ATC R03AL09

Non-exclusive rebate agreements for the specified pharmaceutical products. Open to all interested pharmaceutical companies meeting eligibility criteria. Contract duration: 24 months from earliest start date.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Jul 2025 - Jul 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Jun 03, 2027

Détails de la procédure

Date de publication
15 Jun 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
386697-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30